Study wrapper · #702
Effects of Semax on the Default Mode Network of the Brain.
Editor's note
This is one of the few human studies in this batch: a placebo-controlled resting-state fMRI experiment in 24 healthy volunteers examining whether intranasal 1% Semax alters the brain's default-mode network. Researchers reported a larger volume of the network's rostral (medial frontal cortex) subcomponent in the Semax group versus placebo, 5 and 20 minutes after dosing. The placebo comparison and before/after imaging design is a genuine strength relative to the surrounding rodent literature, but the sample is small, the endpoint is an imaging metric rather than a clinical or cognitive outcome, and randomization and blinding details are limited. Weight it as a small human mechanistic signal that Semax reaches and measurably influences brain networks. Human data, but preliminary and imaging-only.
Plain-language abstract
Most Semax research uses animals; this study looked at healthy people. Twenty-four adults underwent brain scans (a type of MRI that watches the brain at rest) three times: before, and then 5 and 20 minutes after receiving either a Semax nasal spray or a placebo. The researchers focused on the 'default mode network,' a set of brain regions active when the mind is at rest. They found that people given Semax showed a larger active volume in one front part of this network compared with those given placebo. The authors say this confirms Semax affects brain networks and maps where. Because the study was small and measured brain-scan patterns rather than memory, mood, or other real-world outcomes, it shows that Semax measurably influences brain activity but not what that means for health.